Clinical Trials Browser

Phase EARLY_PHASE1 × ulixertinib × 90 days × Clear all

NCT05804227 2026-02-27

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Phase EARLY_PHASE1 Recruiting

Glioma